source
- Vertex reports early kidney drug data, boosting hopes for broad label ahead of next year's pivotal readoutVertex Pharmaceuticals disclosed early data from its experimental kidney disease therapy inaxaplin, showing improvements on a urine-based biomarker. The drug demonstrated positive changes in two s…
- Compass Therapeutics to file BLA for tovecimig despite FDA call for new trialCompass Therapeutics announced it will continue pursuing a biologics license application (BLA) for its bispecific antibody tovecimig aimed at advanced biliary tract cancer, even after the FDA sugge…